MX2008015197A - Metodos de diagnosticar y tratar las complicaciones del embrazo. - Google Patents

Metodos de diagnosticar y tratar las complicaciones del embrazo.

Info

Publication number
MX2008015197A
MX2008015197A MX2008015197A MX2008015197A MX2008015197A MX 2008015197 A MX2008015197 A MX 2008015197A MX 2008015197 A MX2008015197 A MX 2008015197A MX 2008015197 A MX2008015197 A MX 2008015197A MX 2008015197 A MX2008015197 A MX 2008015197A
Authority
MX
Mexico
Prior art keywords
methods
eclampsia
tgf
diagnosing
pregnancy
Prior art date
Application number
MX2008015197A
Other languages
English (en)
Inventor
Ananth S Karumanchi
Vikas P Sukhatme
Mourad Toporsian
Michelle V Letarte
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/443,920 external-priority patent/US7740849B2/en
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of MX2008015197A publication Critical patent/MX2008015197A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Se divulgan en la presente métodos para diagnosticar un desorden hipertensivo relacionado con el embarazo, tal como pre-eclampsia o eclampsia, usando combinaciones de compuestos que alteran los niveles de expresión o la actividad biológica de endoglina soluble, sintasa de óxido nítrico endotelial, PGI2, TGF-?1, TGF-?3, activina A, BMP2, BMP7, y sFlt-1. También se divulgan en la presente métodos para tratar un desorden hipertensivo relacionado con el embarazo, tal como pre-eclampsia y eclampsia, que incluye la medición de cualquiera uno o mas de los siguientes: niveles de expresión o actividad biológica de endoglina soluble, sintasa de óxido nítrico endotelial, PGI2, TCF-?1, TGF-?3, activina A, BMP2, BMP7, y sFlt-1.
MX2008015197A 2006-05-31 2007-05-31 Metodos de diagnosticar y tratar las complicaciones del embrazo. MX2008015197A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/443,920 US7740849B2 (en) 2004-09-24 2006-05-31 Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US85276106P 2006-10-19 2006-10-19
PCT/US2007/012787 WO2008030283A1 (en) 2006-05-31 2007-05-31 Methods of diagnosing and treating complications of pregnancy

Publications (1)

Publication Number Publication Date
MX2008015197A true MX2008015197A (es) 2009-06-23

Family

ID=39157545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008015197A MX2008015197A (es) 2006-05-31 2007-05-31 Metodos de diagnosticar y tratar las complicaciones del embrazo.

Country Status (9)

Country Link
EP (1) EP2029743A4 (es)
JP (1) JP2009538915A (es)
KR (1) KR20090040874A (es)
CN (1) CN101517078A (es)
AU (1) AU2007293475A1 (es)
BR (1) BRPI0713122A2 (es)
CA (1) CA2654283A1 (es)
MX (1) MX2008015197A (es)
WO (1) WO2008030283A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740849B2 (en) 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
SG155257A1 (en) 2004-09-24 2009-09-30 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy
KR20070092737A (ko) 2004-12-15 2007-09-13 베스 이스라엘 데코니스 메디칼 센터 임신 합병증의 진단 및 치료에 유용한 핵산 및 폴리펩티드
WO2009097584A1 (en) * 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
JP2011525241A (ja) * 2008-06-18 2011-09-15 アボット・ラボラトリーズ ＰｌＧＦ−１コンパニオン診断方法および製品
CN104749384B (zh) * 2009-04-23 2017-04-12 沃莱克公司 确定母体健康风险的方法
PT2550535E (pt) * 2010-03-24 2015-09-07 Preelumina Diagnostics Ab Hbf e a1m como marcadores de fase inicial para pré- eclâmpsia
US20130045889A1 (en) * 2010-04-13 2013-02-21 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
US20110251094A1 (en) 2010-04-13 2011-10-13 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
CA2799227C (en) 2010-05-14 2020-06-16 Beth Israel Deaconess Medical Center, Inc. Extracorporeal devices and methods of treating complications of pregnancy
CN102058435B (zh) * 2011-01-17 2012-05-09 北京工业大学 基于理化和血流动力学信息的妊娠期高血压风险监测装置
WO2013000992A1 (en) 2011-06-28 2013-01-03 Vitateq Biotechnology Gmbh Method for diagnosing preeclampsia
ES2714373T3 (es) * 2011-08-01 2019-05-28 Tufts Medical Ct Inc Anticuerpo específico de endoglina para uso en un método de tratamiento de la insuficiencia cardíaca y de afecciones relacionadas
WO2014036440A2 (en) * 2012-08-30 2014-03-06 Ansh Labs Llc Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia
KR101417379B1 (ko) * 2012-10-30 2014-07-10 곽호석 질량분석기를 이용한 태아의 폐 성숙도 진단방법
CN103207274B (zh) * 2013-04-28 2015-02-25 成都中医药大学 一种胎儿7号染色体异常疾病的筛查试剂盒
CN103235142B (zh) * 2013-04-28 2015-04-15 成都中医药大学 一种孕妇初次妊娠筛查试剂盒
US20190105631A1 (en) * 2016-03-31 2019-04-11 ImMutriX Therapeutics, Inc. Method for extracorporeal treatment of preeclampsia and related disorders
CN113919453A (zh) * 2021-09-13 2022-01-11 徐州北之琪农业科技有限公司 用于记录生物特征的区块链集成系统
CN113933129B (zh) * 2021-09-14 2024-01-12 深圳大学 子痫前期诊断试剂盒以及荧光染料的应用
CN115791340B (zh) * 2023-01-17 2023-05-02 北京水木济衡生物技术有限公司 一种子痫复合质控品及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020031513A1 (en) * 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
KR100737945B1 (ko) * 1999-04-16 2007-07-13 예일 유니버시티 유전자 치료 및 치료 스크리닝에 유용한 ｅＮＯＳ 돌연변이
CA2444578C (en) * 2001-04-24 2010-12-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
SG155257A1 (en) * 2004-09-24 2009-09-30 Beth Israel Hospital Methods of diagnosing and treating complications of pregnancy

Also Published As

Publication number Publication date
BRPI0713122A2 (pt) 2012-04-17
CN101517078A (zh) 2009-08-26
JP2009538915A (ja) 2009-11-12
KR20090040874A (ko) 2009-04-27
WO2008030283A1 (en) 2008-03-13
AU2007293475A1 (en) 2008-03-13
CA2654283A1 (en) 2008-03-13
EP2029743A1 (en) 2009-03-04
EP2029743A4 (en) 2010-12-08

Similar Documents

Publication Publication Date Title
MX2008015197A (es) Metodos de diagnosticar y tratar las complicaciones del embrazo.
MX2007003522A (es) Complicaciones del embarazo.
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
WO2006113242A3 (en) Method of increasing testosterone and related steroid concentrations in women
TW200833711A (en) Antibodies to insulin-like growth factor receptor
WO2009036427A3 (en) Prostate cancer biomarkers
WO2007092622A3 (en) Compositions and methods for treating bone
WO2007014335A3 (en) Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
WO2007115045A3 (en) Diagnostics and treatments for tumors
EP2061907A4 (en) TCL1 EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA (LLC) REGULATED BY MIR-29 AND MIR-181
IL177346A0 (en) Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
EA200500232A1 (ru) Способы диагностики и лечения преэклампсии или эклампсии
WO2009142810A3 (en) Methods for treating or preventing colorectal cancer
WO2007009071A3 (en) Methods of diagnosing and treating an inflammatory response
WO2007120787A3 (en) Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
WO2009073905A3 (de) Verfahren zur erhöhung der immunreaktivität
WO2008063776A3 (en) Antibodies to lymphotoxin-alpha
WO2012109282A3 (en) Methods and systems for treating or preventing pregnancy-related hypertensive disorders
WO2010075519A3 (en) Allelic variants associated with advanced age-related macular degeneration
WO2006086772A3 (en) DIAGNOSING AND TREATING CANCER USING β-CATENIN SPLICE VARIANTS
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
WO2008067158A3 (en) METHOD TO PROMOTE HAIR GROWTH AND/OR DELAY OR TREAT HAIR LOSS BY ADMINISTERING A TGF-β ANTAGONIST OR INHIBITOR
WO2010018438A3 (en) Tetrazole glycosides
WO2007090125A3 (en) Prognostic factors for anti-hyperproliferative disease gene therapy
WO2006091930A3 (en) Methods and compounds for promoting vessel regression

Legal Events

Date Code Title Description
FG Grant or registration